Assessment of bone marrow mesenchymal stem cell biological characteristics and support hemotopoiesis function in patients with chronic myeloid leukemia

Leuk Res. 2006 Aug;30(8):993-1003. doi: 10.1016/j.leukres.2005.12.010. Epub 2006 Jan 31.

Abstract

Mesenchymal stem cells (MSCs) are of great therapeutic potential because of their ability to self-renew and differentiate into multiple tissues. Compare to allogenetic MSCs, autologous MSCs from patients needed cell-based therapy may be an ideal alternative stem cell source. However, characteristics of MSCs from a disease state are poorly understood. So, we have isolated and characterized MSCs from choronic myeloid leukemia (CML) patients and compared them with MSCs derived from normal adult bone marrow. Our results showed that CML derived MSCs are similar to normal MSCs in phenotype, morphology and multi-differentiation capacity. Moreover, CML derived MSCs did not express BCR/ABL gene and Ph chromosome, and had not the ability to development tumor in nude mice. At last, they could express hematopoietic cytokines, and possessed hematopoietic supportive ability. These findings indicate that MSCs derived from CML patients' bone marrow may be an attractive tool for clinical needs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Animals
  • Bone Marrow Cells / pathology*
  • Cell Differentiation
  • Cell Line, Tumor
  • Cytokines / genetics
  • Fusion Proteins, bcr-abl / genetics
  • HL-60 Cells
  • Hematopoiesis*
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology*
  • Male
  • Mesenchymal Stem Cell Transplantation
  • Mesenchymal Stem Cells / pathology*
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Middle Aged
  • Neoplasms, Experimental / pathology
  • Philadelphia Chromosome
  • Reverse Transcriptase Polymerase Chain Reaction / methods
  • Xenograft Model Antitumor Assays

Substances

  • Cytokines
  • Fusion Proteins, bcr-abl